Table 2.

Therapeutic strategy of targeting MDSCs in solid tumors

Preclinical models	Therapeutic strategy	Role	References
HepG2 subcutaneous mouse liver cancer models	Curcumin	Suppressed MDSCs expansion and the release of correlated factors GM-CSF and G-CSF	[119]
Hepa1–6 cells orthotopic mouse liver cancer models	Icaritin	Reduced the accumulation and activation of MDSCs, and improved the accumulation and response of CTL	[120]
Samples from liver cancer patients	Metformin	Reversed the effect of MDSCs to T cells	[123]
Ncoa5+/− Male Mice orthotopic mouse liver cancer models	Metformin	Reduced intrahepatic MDSCs and M2 macrophages	[127]
BNL 1ME A.7R.1 cells subcutaneous mouse liver cancer models	Sorafenib	Decreased Tregs and MDSCs	[39]
BNL cells orthotopic mouse liver cancer models	anti-Ly6G Sorafenib	Down-regulation the cell population of Ly6G + MDSCs and enhanced the T cells proliferation	[131]
Hepa 1–6 subcutaneous mouse liver cancer models	Sorafenib compound kushen injection	Diminished MDSCs	[132]
Hepa 1–6 subcutaneous mouse liver cancer models	anti-PD1 YIV-906	Reducing monocytic MDSC, M2- macrophage and M1-like macrophages	[134]